engineered IL-12

Engineered IL-12 refers to a diverse class of modified interleukin-12 (IL-12) molecules designed to improve the therapeutic index of this potent proinflammatory cytokine. Native IL-12 is a heterodimeric cytokine (p35/p40) that stimulates NK cells and T cells to produce IFN-gamma, but its clinical utility has been severely limited by systemic toxicity (e.g., cytokine storm, liver toxicity) and a short half-life. Engineering strategies aim to localize IL-12 activity to the tumor microenvironment (TME) or extend its circulation. Key approaches include: (1) **Stroma-binding/ECM-targeting**, which uses collagen-binding domains (CBD) or other stroma-anchoring motifs to localize the cytokine within the TME, as seen in research from the University of Chicago; (2) **Tumor-activated "pro-cytokines"**, which utilize protease-cleavable masks to restrict activity to the TME (e.g., Xilio's XTX301, Werewolf's WTX-330); (3) **Immunocytokines and Fc-fusions**, which fuse IL-12 to tumor-targeting antibodies or Fc regions to improve pharmacokinetics and localization (e.g., Merck KGaA's M9241, Dragonfly's DF6002); and (4) **Genetic delivery**, employing mRNA or DNA vectors for local intratumoral expression (e.g., AstraZeneca's MEDI1191, Celsion's GEN-1). These agents are primarily investigated for solid tumors, often in combination with immune checkpoint inhibitors or myeloid-polarizing agents like engineered GM-CSF.

Other names

modified interleukin-12targeted IL-12tumor-activated IL-12stroma-binding IL-12collagen-binding IL-12IL-12-Fc fusion proteinIL12-Fc fusion proteinIL 12-Fc fusion protein